If you thought all IPOs that listed during the pandemic turned out to be flops, you'd be wrong - because IPD Group (ASX:IPG) has been one exception. It has grown from a $100m company to a >$350m company in less than 4 years. But it is off its all time highs. Where to next?
What are…
It seems the Albanese government is keen for Boomers to shoulder more of the tax burden than they are right now, and for younger generations to pay less. Don't take our word for it - last week's Productivity Summit saw an entire day dedicated to discussion of the tax system and it was a consensus…
Dominos Pizza Enterprises (ASX:DMP) is now less than 10% of what it was in mid-2021 - how can this be when fast-food stocks are meant to be recession proof and immune to inflation?The company's share price was inflated during the pandemic as locked down consumers ordered pizza at home. As restaurants opened again and interest…
When we last wrote about Tabcorp (ASX: TAH) in June 2024, we said that,' it had been through a dog of a year, with its share price dropping roughly 40% in the last 12 months'.The company faced intense competition from online players, has fought off takeover attempts, merged with Tatts Group then demerged its lotteries…
Think of 'America First' ASX stocks and Island Pharmaceuticals (ASX:ILA) typically hasn't come to mind, but its acquisition of Galidesivir should put it firmly in the list. You cannot question the data that the company is in possession of, but some investors may think a company with plans to undertake an 'animal study' is years…
What a volatile FY25 it as for WiseTech. Just look at all that it went through:Richard White was going to depart, but he ultimately prevailed over his enemies,
The company unveiled one of the biggest buys in its history, only to see customers of its target company not like the deal,
Shares…
Nova Eye Medical (ASX:EYE) is no clinical stage medtech company, but has just an exciting 12 months ahead as if it was a clinical stage company with company-making catalysts ahead.Because even though it has commercialised its devices, a major 12 months are ahead during which it is expected to make major inroads in the US…
Here are 5 ASX biotechs expecting clinical trial results in the next few months!
Dimerix (ASX:DXB)
Dimerix is in the middle of a Phase III trial or its DMX-200 drug for a condition known as Focal Segmental Glomerulosclerosis (FSGS). For patients with FSGS, the kidneys’ ability to purify (clean) the blood is impaired. This can…
Is Skycity Entertainment Group (ASX:SKC) on the same path as Star? On one hand, it may sound preposterous as it has revenues just about the same as it was pre-COVID and it is profitable. The other, it announced a $240m capital raising the same day as its annual results and is seeing customers spend less…
Each reporting season, we like to recap some of the best annual results on the ASX and some of the worst as well. Amidst all the companies, it is easy for investors to get lost amidst the mire of information. And so we like to single out particular companies that impressed and others that did…
